Rezafungin
A once-weekly echinocandin antifungal for candidaemia
Rezafungin is an echinocandin, a cyclic lipopeptide antifungal, engineered to be stable enough to last about six days in the blood. Approved as Rezzayo in 2023, it is given once a week, where older echinocandins are given daily, for candidaemia and invasive candidiasis when other options are limited.
Manufacturer's recommended dosing (FDA label): 400 mg, Once (week 1), Intravenous infusion Details ↓
Recommended Dosing
Manufacturer's recommended dosing (FDA label)
From the prescribing information. Other doses studied, if any, are in the full dosing data below.
What is it?
Rezafungin shares the echinocandin mechanism of blocking the fungal cell-wall enzyme beta-(1,3)-D-glucan synthase. Its structure resists breakdown, giving a terminal half-life of about 152 hours in patients, so a 400 mg loading dose followed by 200 mg once a week maintains exposure. The label says it is not a clinically relevant substrate of CYP450 enzymes.
In the phase 3 ReSTORE trial, 199 patients with candidaemia or invasive candidiasis received weekly rezafungin or daily caspofungin. Day-30 death or unknown survival was 24% against 21%, and global cure at day 14 was 59% against 61%, meeting noninferiority. Pooled with the phase 2 STRIVE trial and ReSTORE's China cohort, 372 patients in all, day-30 mortality was 20% against 22%, and blood cultures cleared faster on rezafungin (a median 23 against 37 hours).
The high early exposure from the loading dose is the point of the design. In a pooled look at the first week, it was already non-inferior by day 7, which its investigators present as a reason to test shorter treatment. Patients in intensive care did about as well as in the overall trials.
Its trials found no species it handled worse. In ReSTORE, outcomes for Candida albicans, C. glabrata and C. tropicalis were similar on both drugs and did not track minimum inhibitory concentrations; among patients whose culture was positive close to randomisation, mycological eradication by day 5 was 71% on rezafungin against 50% on caspofungin, a difference that did not reach significance.
Its weekly schedule is also why doctors reach for it outside the trials. In a Spanish series, the reasons were fluconazole-resistant isolates, finishing treatment as an outpatient without a daily line, and avoiding azole drug interactions; small case series report its use in intra-abdominal infection. Those are observational reports, not trial evidence.
FDA approved it as Rezzayo on March 22, 2023, for patients with limited or no alternative options, noting approval rests on limited clinical data; the current label covers adults and children 12 and older, and safety beyond four weekly doses has not been established. The label warns of hypersensitivity including anaphylaxis, infusion reactions such as flushing and chest tightness, photosensitivity and liver reactions.
Mechanism of Action
Rezafungin is a long-acting echinocandin: it blocks fungal cell-wall synthesis and lasts long enough to be given once a week.
Glucan synthase
Inhibits 1,3-beta-D-glucan synthase, stopping Candida from building its cell wall.
Weekly dosing
A structure resistant to breakdown gives a terminal half-life of about 152 hours (label 12.3).
Front-loaded exposure
The 400 mg loading dose gives high early levels; blood cultures cleared faster than on caspofungin in pooled trials.
Published Research
The studies behind rezafungin, from their PubMed abstracts.
ReSTORE: phase 3 against caspofungin
In 199 patients, global cure at day 14 was 59% on weekly rezafungin and 61% on daily caspofungin, and death or unknown survival at day 30 was 24% against 21%, meeting the EMA and FDA noninferiority endpoints.
Pooled ReSTORE and STRIVE
Across 294 patients, day-30 all-cause mortality was 19% in both groups; mycological eradication by day 5 occurred in 73% on rezafungin and 65% on caspofungin, with similar safety.
STRIVE: phase 2
In 207 patients, overall cure was 76.1% on the 400/200 mg rezafungin regimen against 67.2% on caspofungin, with 30-day all-cause mortality of 4.4% against 13.1%; candidaemia cleared in about 20 hours in both groups.
Patients in intensive care
Among 113 ICU patients pooled from STRIVE and ReSTORE, day-30 all-cause mortality was 34.8% on rezafungin against 25.4% on caspofungin, while mycological eradication at day 5 was higher (78.3% against 59.7%) and blood cultures cleared faster (median 18 against 38 hours).
ReSTORE's China cohort
In 55 patients from China, 30-day mortality was 33.3% on weekly rezafungin and 35.7% on daily caspofungin, with similar global cure at day 14 (48.1% against 46.4%).
Salvage and consolidation in practice
In 13 Spanish patients given rezafungin after other antifungals, the reasons were fluconazole resistance (54%), allowing outpatient treatment (31%) and avoiding azole interactions (15%); none received it first line.
All randomised patients pooled
Pooling 372 patients from STRIVE, ReSTORE and its China cohort, day-30 mortality was 20% on rezafungin and 22% on caspofungin, and the median time to a negative blood culture was shorter (23.1 against 36.7 hours).
The first week
In a pooled analysis of the first week, rezafungin was non-inferior to caspofungin from day 7: mortality 7.9% against 5.2%, mycological eradication 71.2% against 65.2%; the authors present it as a basis for testing shorter courses.
Intra-abdominal candidiasis case series
In 8 patients with intra-abdominal Candida infection, 6 also with candidaemia, eradication was reached within 14 days in 7, including some with incomplete source control; two died within 30 days and no adverse events were reported.
Outcomes by Candida species
In ReSTORE's 187 analysed patients, cure, eradication and mortality were comparable on both drugs for C. albicans, C. glabrata and C. tropicalis, and did not appear to depend on minimum inhibitory concentrations; only two isolates were non-susceptible.
Fresh positive cultures
In 84 ReSTORE patients with a positive Candida culture close to randomisation, day-5 eradication was 71.1% on rezafungin against 50.0% on caspofungin, with day-30 mortality of 26.3% against 21.7%; neither difference was significant.
How the FDA approved it
FDA reviewers explain that the 2023 approval for candidaemia and invasive candidiasis in adults with limited alternatives rested on a single phase 3 trial showing non-inferior day-30 mortality against another echinocandin (20% margin); a neurotoxicity signal seen in monkeys was not reflected in the clinical safety data.
Dosing Data
Rezzayo is infused intravenously once a week: a 400 mg loading dose, then 200 mg weekly; a missed dose given within 3 days keeps the schedule.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
The approved product, as its label describes it:
- Rezzayo (rezafungin injection): For injection: 200 mg as a solid (cake or powder) in a single-dose vial for reconstitution. Forms the label lists: single-dose vials.
Source: Rezzayo (rezafungin injection) label, section 3 (DailyMed version 5, effective July 1, 2026).
Mixing a vial: a worked example
Nothing to mix at home, and no syringe units to work out: Rezafungin is prepared and given by clinical staff, in hospital or an infusion clinic.
Its US label is for candidaemia and invasive candidiasis and says it is for infusion into a vein only, after dilution.
Source: Rezzayo (rezafungin injection) label, section 2 (DailyMed version 5, effective July 1, 2026).
Storage before and after mixing
Before mixing or first use: “Storage and Handling REZZAYO Vials REZZAYO vials should be stored at 20°C to 25°C (68°F to 77°F).” “Do not freeze.”
After mixing or first use: “Reconstituted Solution REZZAYO reconstituted solution can be stored between 5°C (41°F) and 25°C (77°F) for up to 24 hours.” “Storage of the Reconstituted Solution REZZAYO reconstituted solution can be stored between 5°C to 25°C (41°F to 77°F).” “Stability of the reconstituted solution has been demonstrated for 24 hours when stored at 5°C to 25°C (41°F to 77°F).”
The label also sets storage out in a table that does not read well out of context: see section 16 of the label linked below.
Source: Rezzayo (rezafungin injection) label, sections 16 and 2 (DailyMed version 5, effective July 1, 2026).
How it is taken
As the approved label gives it: Intravenous infusion (Once (week 1); Label: candidaemia and invasive candidiasis, adults and children 12 and older, loading dose).
Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of terminal half-life 152 ± 29 hours in patients. After about five half-lives almost none is left.
How long the doses were given: Label: candidaemia and invasive candidiasis, adults and children 12 and older, loading dose: First dose; Label: maintenance: Safety not established beyond 4 weekly doses.
When effects appear: unknown; no source on this page gives a time to effect for Rezafungin. Results reported in the studies are under Published Research.
Source: half-life: Rezzayo prescribing information, section 12.3 (DailyMed set 90073508, effective July 1, 2026); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Safety profiles similar to caspofungin in the pooled trials; Treatment-emergent adverse events were common in both groups of these seriously ill patients. Full list and cautions ↓
When the label says to stop or get help:
- Hypersensitivity Reactions, including Anaphylaxis: Cases of serious hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving REZZAYO. If these reactions occur, discontinue REZZAYO and administer appropriate treatment.
Source: Rezzayo (rezafungin injection) label, boxed warning and section 5 (DailyMed version 5, effective July 1, 2026); the Side Effects section below (“From the studies above”).
Interactions
- CYP probe substrates, transporter substrates, immunosuppressants and cancer therapies: two phase 1 crossover studies in healthy subjects found no clinically meaningful drug-drug interactions
Every peptide's record, with its source: the interaction matrix.
Source: human study, PMID 37154682.
Checking what you bought
Unknown: no published independent test of Rezafungin products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: FDA Approved (Approved in the US as Rezzayo, NDA 217417, on March 22, 2023, for candidaemia and invasive candidiasis in patients with limited or no alternative treatment options). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
Warnings from the Rezzayo label (DailyMed, effective July 1, 2026).
Legal Status
Rezafungin is an approved prescription drug in the US.
Frequently Asked Questions
?What is Rezzayo?
Rezzayo is rezafungin, an echinocandin antifungal given by intravenous infusion once a week for candidaemia and invasive candidiasis in patients with limited or no other options.
?How does rezafungin differ from caspofungin?
Both block the same fungal cell-wall enzyme, but rezafungin's half-life of about six days allows once-weekly dosing, while caspofungin is given daily. In the ReSTORE trial the two had similar cure and survival rates.
?Why is it approved only when options are limited?
FDA's approval is based on limited clinical safety and efficacy data, and safety beyond four weekly doses has not been established, so the indication is restricted.
?What happens if a weekly dose is missed?
The label says give it as soon as possible; if that is within 3 days of the scheduled day, the next dose stays on schedule, otherwise the schedule is reset.
?Does it clear the blood faster than caspofungin?
In pooled trial data, the median time to a negative blood culture was about 23 hours against 37, though mortality and cure rates were similar.
References
- [fda] US FDA, Drugs@FDA (openFDA): REZZAYO, NDA 217417 (March 22, 2023). Read October 3, 2026.
- [fda-pi] FDA. Rezzayo (rezafungin) US prescribing information (DailyMed set 90073508-6dca-4d27-aa5a-ed837737c35b, version 5, effective July 1, 2026). Read October 3, 2026.
- [clinical-trial] Thompson GR 3rd, et al. "Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial." Lancet, 2023;401(10370):49-59. PMID: 36442484.
- [pubmed] Thompson GR 3rd, et al. "Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials." Lancet Infect Dis, 2024;24(3):319-328. PMID: 38008099.
- [clinical-trial] Thompson GR, et al. "Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial." Clin Infect Dis, 2021;73(11):e3647-e3655. PMID: 32955088.
- [pubmed] Honoré PM, et al. "Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials." Crit Care, 2024;28(1):348. PMID: 39468640.
- [clinical-trial] Huang H, et al. "Efficacy and Safety of Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis in a China Cohort of a Double-Blind, Randomised, Phase 3 Trial (ReSTORE China)." Mycoses, 2025;68(11):e70122. PMID: 41194465.
- [pubmed] Boán J, et al. "Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real-World Clinical Practice." Mycoses, 2026;69(2):e70163. PMID: 41718446.
- [pubmed] Soriano A, et al. "Rezafungin Versus Caspofungin in Candidaemia and Invasive Candidiasis: A Post Hoc Pooled Analysis of Phase 2 and Phase 3 Trials." Mycoses, 2026;69(7):e70205. PMID: 42460544.
- [pubmed] Ostrosky-Zeichner L, et al. "Exploring Early Antifungal Activity of Rezafungin as a Stepping-Stone for Shorter Treatment Duration for Candidemia: Pooled Analysis of 2 Randomized Trials." Open Forum Infect Dis, 2026;13(4):ofag143. PMID: 41940006.
- [pubmed] Diella L, et al. "Is there a role for rezafungin in intra-abdominal Candida spp. infections? A case series and literature review." J Mycol Med, 2026;36(3):101641. PMID: 42574798.
- [fda-pi] Rezzayo (rezafungin for injection) US prescribing information (Melinta; DailyMed set 90073508, version 5, effective July 1, 2026), sections 2.1, 2.2 and 5; read through openFDA October 6, 2026.
- [pubmed] Locke JB, et al. "Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis." Antimicrob Agents Chemother, 2024;68(5):e0158423. PMID: 38526046.
- [pubmed] Soriano A, et al. "Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study." Clin Infect Dis, 2024;79(3):672-681. PMID: 38985561.
- [pubmed] Smith HL, et al. "Regulatory Considerations in the Approval of Rezafungin (Rezzayo) for the Treatment of Candidemia and Invasive Candidiasis in Adults." J Infect Dis, 2024;230(2):505-513. PMID: 38502709.
Sources & Citations
Studies were read from their PubMed abstracts; the Rezzayo label from DailyMed (set 90073508, effective July 1, 2026) through openFDA, read October 6, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.